Blue Earth Products

Blue Earth Diagnostics is a leading molecular imaging company specializing in the development and commercialization of innovative PET radiopharmaceuticals for oncology. The company is best known for Axumin (fluciclovine F 18), the first FDA-approved F-18 PET imaging agent for recurrent prostate cancer, and Posluma (flotufolastat F 18), a high-affinity PSMA-targeted imaging agent. Acquired by Bracco Imaging in 2019, Blue Earth Diagnostics continues to advance its pipeline of precision radiopharmaceuticals, including applications in neuro-oncology. The company's expertise lies in identifying and developing radiolabeled compounds that address significant unmet needs in cancer diagnosis and management, providing actionable insights to clinicians.